Compare Carparts.Com Inc (PRTS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carparts.Com Inc vs Sanofi SA — how do they compare? Carparts.Com Inc trades at $8.63 (market cap $66.42M), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 1433× Carparts.Com Inc's market cap, and Sanofi SA pays a 6.01% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Carparts.Com Inc for 45 Days and Sanofi SA for 94 Days on average.
| PRTS | SNY | |
|---|---|---|
Market Cap | $66.42M | $95.18B |
Volume | 40,287 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $52.34 |
52-Week Low | $3.88 | $39.51 |
Typical Hold Time | 45 Days | 94 Days |
Enterprise Value | $79.39M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRTS trades at $8.51, down 2.13% today, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats but remains unprofitable with negative margins. Revenue has declined from $676M in 2023 to $548M in 2025, though net losses improved in recent quarters. Analyst sentiment is positive with 60% buy ratings.
The outlook balances technical strength against fundamental challenges. While the stock shows bullish momentum and analyst support, persistent losses and declining revenue pose significant risks. Investment opportunity exists if the company can stabilize revenue and achieve profitability, but current financial performance warrants caution despite positive earnings surprises.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
